WO2012144726A3 - 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자 - Google Patents

폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자 Download PDF

Info

Publication number
WO2012144726A3
WO2012144726A3 PCT/KR2012/000928 KR2012000928W WO2012144726A3 WO 2012144726 A3 WO2012144726 A3 WO 2012144726A3 KR 2012000928 W KR2012000928 W KR 2012000928W WO 2012144726 A3 WO2012144726 A3 WO 2012144726A3
Authority
WO
WIPO (PCT)
Prior art keywords
polo
kinase
tumor antigen
genes
proteins
Prior art date
Application number
PCT/KR2012/000928
Other languages
English (en)
French (fr)
Other versions
WO2012144726A2 (ko
Inventor
김태규
Original Assignee
한국보건산업진흥원
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국보건산업진흥원, 가톨릭대학교 산학협력단 filed Critical 한국보건산업진흥원
Priority to US14/113,046 priority Critical patent/US9072690B2/en
Publication of WO2012144726A2 publication Critical patent/WO2012144726A2/ko
Publication of WO2012144726A3 publication Critical patent/WO2012144726A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11021—Polo kinase (2.7.11.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 폴로-유사 키나아제 1(Polo-like kinase 1) 유래의 종양항원 단백질 또는 유전자에 관한 것으로, 폴로-유사 키나아제 1 유래의 단백질 또는 이들과 기능적으로 동등한 특성을 갖는 변이체가 MHC 클래스Ⅰ 항원 또는 Ⅱ 항원과 결합하여 복합체를 형성함으로써 상기 복합체가 세포독성 T 림프구에 의해 인식될 수 있는 종양항원임을 규명함으로써 범용 종양의 면역치료에 이용할 수 있다.
PCT/KR2012/000928 2011-04-21 2012-02-08 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자 WO2012144726A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/113,046 US9072690B2 (en) 2011-04-21 2012-02-08 Tumor antigen proteins or genes of polo-like kinase 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0037522 2011-04-21
KR1020110037522A KR101807162B1 (ko) 2011-04-21 2011-04-21 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자

Publications (2)

Publication Number Publication Date
WO2012144726A2 WO2012144726A2 (ko) 2012-10-26
WO2012144726A3 true WO2012144726A3 (ko) 2012-12-20

Family

ID=47041998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000928 WO2012144726A2 (ko) 2011-04-21 2012-02-08 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자

Country Status (3)

Country Link
US (1) US9072690B2 (ko)
KR (1) KR101807162B1 (ko)
WO (1) WO2012144726A2 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646352B1 (ko) 2014-10-16 2016-08-08 현대자동차주식회사 차량용 다단 자동변속기
KR101646353B1 (ko) 2014-10-16 2016-08-08 현대자동차주식회사 차량용 다단 자동변속기
KR101646362B1 (ko) 2014-10-22 2016-08-05 현대 파워텍 주식회사 다단 자동변속기 파워트레인
KR101646373B1 (ko) 2014-11-04 2016-08-05 현대자동차주식회사 차량용 다단 자동변속기
KR101693933B1 (ko) 2014-11-04 2017-01-06 현대자동차주식회사 차량용 다단 자동변속기
KR101970709B1 (ko) 2017-06-13 2019-04-22 가톨릭대학교 산학협력단 ＰＬＫ１ 단백질에 대한 항원―특이 Ｔ 세포 면역반응을 유도하는 ＨＬＡ―Ａ２ 아형―특이 ＰＬＫｌ―유래 항원결정기
KR20210090561A (ko) * 2020-01-10 2021-07-20 주식회사 엘지화학 Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358738B1 (en) * 1998-05-13 2002-03-19 The President And Fellows Of Harvard College Polo box therapeutic compositions, methods, and uses therefor
JP2008526760A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIRGIT SPANKUCH-SCHMITT ET AL.: "Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells", ONCOGENE, vol. 21, no. 20, 2002, pages 3162 - 3171, XP001180957, DOI: doi:10.1038/sj.onc.1205412 *
DATABASE NCBI 17 April 2011 (2011-04-17), accession no. M 011121 *
JUNG-SUN PARK ET AL.: "Topoisomerase || alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2Kb-restricted T cell epitope", CANCER IMMUNOL. IMMUNOTHER., vol. 59, no. 5, 2010, pages 747 - 757, XP019800196 *

Also Published As

Publication number Publication date
KR101807162B1 (ko) 2017-12-11
WO2012144726A2 (ko) 2012-10-26
US9072690B2 (en) 2015-07-07
US20140105923A1 (en) 2014-04-17
KR20120119538A (ko) 2012-10-31

Similar Documents

Publication Publication Date Title
WO2012144726A3 (ko) 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
AU2012222463A8 (en) Cea antibodies
CA2868907C (en) Anti-hla-b*27 antibodies and uses thereof
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2014125374A3 (en) Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
WO2013188693A8 (en) Antigen binding constructs to cd3
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
RU2018132044A (ru) Антитела против тау
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
NZ607969A (en) Cd33 binding agents
WO2012032181A3 (en) Antibody derivatives
WO2013054199A3 (en) Cmv antigens and uses thereof
MX2015003541A (es) Metodos para identificar los anticuerpos con inmunogenia reducida.
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
WO2012125733A3 (en) Antibody screening methods
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
WO2014125377A3 (en) Highly galactosylated anti-her2 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12773995

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14113046

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12773995

Country of ref document: EP

Kind code of ref document: A2